a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties
A.I.dvisor tells us that OCX and FONR have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCX and FONR's prices will move in lockstep.
| Ticker / NAME | Correlation To OCX | 1D Price Change % | ||
|---|---|---|---|---|
| OCX | 100% | -4.76% | ||
| FONR - OCX | 30% Poorly correlated | -1.46% | ||
| VNRX - OCX | 21% Poorly correlated | -5.76% | ||
| ELUT - OCX | 21% Poorly correlated | +2.13% | ||
| INBS - OCX | 21% Poorly correlated | -10.59% | ||
| WRBY - OCX | 20% Poorly correlated | +1.04% | ||
More | ||||
| Ticker / NAME | Correlation To OCX | 1D Price Change % |
|---|---|---|
| OCX | 100% | -4.76% |
| non-invasive theme (5 stocks) | 43% Loosely correlated | +3.94% |
| cancer theme (82 stocks) | 10% Poorly correlated | -2.35% |
| Medical Specialties theme (427 stocks) | 6% Poorly correlated | -1.35% |
| Medical Specialties theme (417 stocks) | 6% Poorly correlated | -1.54% |
| diagnostics theme (23 stocks) | 5% Poorly correlated | -3.17% |
More | ||